Perftoran improves Visudyne-photodynamic therapy via suppressing hypoxia pathway in murine lung cancer

Gamal‐Eldeen, Amira M.; Alrehaili, Amani A.; Alharthi, Afaf; Banjer, Hamsa Jameel; Raafat, Bassem M.; Hawsawi, Nahed M.

doi:10.1016/j.jrras.2022.03.011

Cited by 1 publication

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the projected 127,070 deaths from lung cancer in 2023, around 103,000 (81%) are expected to be directly attributed to cigarette smoking, while an additional 3560 deaths will be caused by exposure to second-hand smoke [ 17 ]. Current treatment methods for lung cancer often exhibit significant systemic toxicity, limited response rates, and poor survival outcomes, emphasizing the urgent need to develop non-invasive and effective therapeutic approaches that cater to the specific needs of lung cancer patients [ 18 ].…”

Section: Lung Cancermentioning

confidence: 99%

“…However, it is worth noting that PDT efficacy may be influenced by hypoxia [ 18 , 36 ]. In an in vivo study, the impact of Perftoran ® administration, an oxygen carrier, on the efficiency of Visudyne ® /PDT and its effect on the hypoxia pathway in a murine lung cancer model were investigated.…”

Section: Lung Cancermentioning

confidence: 99%

“…This combination treatment led to necrosis in the bronchiolar epithelium, with the accumulation of necrotic debris and late apoptosis. Additionally, this combination effectively suppressed hypoxia levels, inhibited HIF-1α concentration, and reduced vascular endothelial growth factor (VEGF) expression [ 18 ].…”

Section: Lung Cancermentioning

confidence: 99%

See 2 more Smart Citations

Recent Studies in Photodynamic Therapy for Cancer Treatment: From Basic Research to Clinical Trials

Kim,

Chang

2023

Pharmaceutics

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an emerging and less invasive treatment modality for various types of cancer. This review provides an overview of recent trends in PDT research, ranging from basic research to ongoing clinical trials, focusing on different cancer types. Lung cancer, head and neck cancer, non-melanoma skin cancer, prostate cancer, and breast cancer are discussed in this context. In lung cancer, porfimer sodium, chlorin e6, and verteporfin have shown promising results in preclinical studies and clinical trials. For head and neck cancer, PDT has demonstrated effectiveness as an adjuvant treatment after surgery. PDT with temoporfin, redaporfin, photochlor, and IR700 shows potential in early stage larynx cancer and recurrent head and neck carcinoma. Non-melanoma skin cancer has been effectively treated with PDT using methyl aminolevulinate and 5-aminolevulinic acid. In prostate cancer and breast cancer, PDT research is focused on developing targeted photosensitizers to improve tumor-specific uptake and treatment response. In conclusion, PDT continues to evolve as a promising cancer treatment strategy, with ongoing research spanning from fundamental investigations to clinical trials, exploring various photosensitizers and treatment combinations. This review sheds light on the recent advancements in PDT for cancer therapy and highlights its potential for personalized and targeted treatments.

show abstract

Section: Lung Cancermentioning

confidence: 99%

Section: Lung Cancermentioning

confidence: 99%